KR

Keros Therapeutics IncNASDAQ KROS Stock Report

Last reporting period 30 Sep, 2024

Updated 20 Nov, 2024

Last price

Market cap $B

2.086

Small

Exchange

XNAS - Nasdaq

KROS Stock Analysis

KR

Uncovered

Keros Therapeutics Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-6/100

Low score

Market cap $B

2.086

Dividend yield

Shares outstanding

28.535 B

Keros Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Lexington, Massachusetts and currently employs 105 full-time employees. The company went IPO on 2020-04-08. The firm is focused on the discovery, development and commercialization of treatments for patients suffering from hematological and musculoskeletal disorders with unmet medical need. Its protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes (MDS) and myelofibrosis. Its lead small molecule product candidate, KER-047, is being developed for the treatment of anemia resulting from iron imbalance. Its third product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension (PAH), and for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta. Its KER-050 is an engineered ligand trap comprised of a modified ligand-binding domain of the transforming growth factor-beta (TGF-B) receptor.

View Section: Eyestock Rating